Compare PRPO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | FEMY |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 37.2M |
| IPO Year | 2000 | 2021 |
| Metric | PRPO | FEMY |
|---|---|---|
| Price | $26.86 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 8.4K | ★ 419.8K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.03 | 8.60 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,532,000.00 | $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 21.95 | ★ 51.97 |
| 52 Week Low | $4.90 | $0.31 |
| 52 Week High | $29.53 | $1.76 |
| Indicator | PRPO | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 54.52 |
| Support Level | $22.58 | $0.54 |
| Resistance Level | $28.38 | $0.58 |
| Average True Range (ATR) | 1.52 | 0.04 |
| MACD | 0.33 | 0.01 |
| Stochastic Oscillator | 66.14 | 85.66 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.